Shares of Maravai Lifesciences Holdings, Inc. (MRVI, Financial) experienced a significant increase, rising by 5.11%. The stock is currently priced at $8.02 per share, with a trading volume of 430,780 shares and a turnover rate of 0.30%. The stock's amplitude is noted at 5.37%.
Recent financial results indicated that Maravai reported revenue of $73.40 million, but with a net loss of $7.59 million, translating to an earnings per share of -$0.06. The gross profit stood at $28.26 million, and the price-to-earnings ratio is at -8.02.
In terms of analyst ratings, out of 15 institutions, 73% issued a buy recommendation, and 27% suggested holding the stock, while none advised selling.
Within the biotechnology sector, which recorded an overall increase of 1.56%, several stocks demonstrated significant performance. Notable gainers included Tc Biopharm, Revolution Medicines, and Nrx Pharmaceuticals. Actively traded stocks in the sector were Aditxt, Conduit Pharmaceuticals, and Windtree Therapeutics, showing high turnover rates. Stocks with the highest volatility were Conduit Pharmaceuticals, Klotho Neurosciences, and Tc Biopharm.
Maravai Lifesciences Holdings Inc. is a life sciences company specializing in nucleic acid production, biologics safety testing, and protein detection. The majority of its revenue comes from the nucleic acid production segment, which focuses on meeting the needs of research, therapy, and vaccine programs. The company also provides research products for protein labeling and detection in cell and tissue samples.
